Pharmas Join To Build Inflammation Biomarkers In Alzheimer's, Depression
Drug firms exploring link between inflammation and central nervous system disorders are now sharing resources through public/private Biomarkers Consortium project.
You may also be interested in...
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
J&J's Janssen unit is ending development of atabecestat after serious elevations of liver enzymes were seen in some patients who received the drug, increasing doubts about the BACE inhibitor mechanism as an appropriate target.
US FDA revises draft guidance issued in 2013 to allow research targeting cognition as single endpoint and studies solely evaluating biomarkers; document offers 'potential for multiple advances,' Alzheimer's Association says.